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Treatment of L5178Y in vitro cells with ara-c (10 M) 
or asparaginase (0.5 lU/ml) for" "8 hours resulted, in 45% 
and 24% viability, respectively; simultaneous exposure 
to both drugs resulted in 25% viability, a subadditive ef¬ 
fect. Sequential 8 hour treatments with asparaginase 
preceding ara-c or ara-c preceding asparaginase resulted 
in 43% and 8% viability, respectively, indicating strong 
schedule-dependency. While ara-c pretreatment resulted 
in cell synchronization it did not enhance asparaginase- 
induced inhibition of DNA and protein synthesis. In vivo 
recovery from drug-induced inhibition of cell growth suggested 
an optical interval of 120 hours. Mice were inoculated 
with 10 cells. Treatment with asparaginase, ara-c or both 
drugs on day 3 resulted in mean survival times (MST) of 16, 
21 and 18 days, respectively (control MST 10 days). With 
a 120 hour interval between the 2 drugs, asparaginase 
preceding ara-c resulted in a MST of 23 days; ara-c preceding 
asparaginase produced 20/24 60 day survivors. Maximal weight 
loss was only 10%. Mechanisms for the antagonism include 
asparaginase-induced decreased transport and incorporation 
of ara-c into macromolecules and cytokinetic mistiming. 
Unequivocal understanding of the apparent synergy is not 
adequately explained by the observed AC-induced synchronization. 
Since both drugs are likely components of antileukemic 
combinations, understanding of such drug-drug interactions would 
optimize clinical therapy. 
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A variety of drug interactions, ranging from antagonism to 
synergism, can result from the combination of two cancer chemothera¬ 
peutic agents. There is a growing interest in understanding the 
basis of these interactions since various studies have indicated 
the superiority of combination therapy for the treatment of acute 
leukemia (34, 40, 46, 60, 114, 125, 150). Two agents that have been 
studied for remission induction in acute lymphocytic and acute 
myelogenous leukemia are cytosine arabinoside (ara-c) and L-aspara- 
ginase (9, 54, 112, 144). Even though their combined use has pro¬ 
duced encouraging results in the therapy of acute lymphocytic leu¬ 
kemia (46, 60, 114, 125), few studies have attempted to determine 
the optimal schedule of administration or to define the nature of 
their interactions. 
An aim in designing combination chemotherapy is to select 
agents which will maximize tumor cell kill while minimizing host 
toxicity. This can be accomplished with agents like ara-c and 
asparaginase, which have different host toxicities (9, 54, 101). 
This will work, of course, provided that their interaction does not 
antagonize their antitumor activity as, for example, asparaginase 
antagonizing the cytotoxicity of another chemotherapeutic agent, 
methotrexate (22, 23, 25). Capizzi et al. (22, 23, 25) demonstrated 
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both schedule dependent synergism and antagonism for the combination 
of asparaginase and methotrexate. In brief, when asparaginase 
preceded methotrexate by less than 2H hours, the effect of metho¬ 
trexate on murine leukemia L5178Y cells was diminished. However, 
when the reverse combination was tried, there was no antagonism. 
In fact, asparaginase protects mice against methotrexate-induced 
intestinal lesions when asparaginase followed methotrexate. From 
this work it can be concluded that there is a synergistic antitumor 
schedule that also minimizes host toxicity. 
Although methotrexate and ara-c have different intracellular 
mechanisms of action (22, 25, 55, 75, 82, 165) they are both active 
agents in inhibiting DNA synthesis. Therefore, the main purpose of 
this thesis project was to determine if the combination of ara-c 
and asparaginase also exhibits schedule-dependency. Studies reported 
in this thesis describe the effect of three different treatment sched¬ 
ules on animal survival and cell viability ±n_ vitro using the animal 
tumor model, murine leukemia L5173Y. In addition, in an attempt 
to explain the interactions observed, the effect of this combina¬ 







Ara-c (cytosine arabinoside, 1-B-D arabinofuranosylcytosine, 
Cytosar, Cytarabine) is a pyrimidine nucleoside analog of deoxy- 
cytidine, but differing in that the sugar moiety is arabinose 
rather than deoxyribose (95, 102). Ara-c is of considerable clinical 
importance because of its effectiveness against acute leukemia— 
particularly the acute myelogenous form—in man (9, 54). The 
brief review presented here will summarize some of the aspects of 
ara-c's cellular uptake, intracellular mechanism of action, and 
clinical use. 
Ara-c passively diffuses into cells, where it is rapidly 
phosphorylated to the active form, ara-CTP (29, 31s 79, 104). In¬ 
deed, there appears to be a relationship between the ability of 
human and mouse leukemic cells to retain ara-c in its phosphorylated 
form, and the susceptibility of the cells to the drug (29, 79)• 
On the other hand, resistance of cells to ara-c has been correlated 
with decreased levels of deoxycytidine kinase (136), the enzyme 
responsible for the phosphorylation of both ara-c and deoxycytidine 
to their respective monophosphates (ara-CMP, dCMP) (44, 79, 104). 
In addition, resistance to ara-c is also associated with enhanced 
levels of pyrimidine nucleoside deaminase which is the enzyme that 
6 
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catalyzes the conversion of ara-c to its Inactive metabolite, 
uracil arabinoside (4l, 65). 
The importance of deoxycytidine kinase in ara-c metabolism has 
pronpted the investigation of the interaction between ara-c and 
the enzyme's natural substrate, deoxycytidine. Since the Km of the 
kinase for ara-c is three-fold higher than the Km for deoxycytidine, 
the phosphorylation of ara-c is markedly inhibited in the presence 
of deoxycytidine (104, 136). This fact has been invoked to explain 
the ability of deoxycytidine to partially rescue ara-c treated cells 
(104, 136). In addition, the phosphorylated products of ara-c and 
deoxycytidine (dCTP, ara-CTP) have been reported to be feedback 
inhibitors of deoxycytidine kinase (44, 103). Although ara-CTP 
would appear to inhibit its own synthesis, it has, however, only a 
weak effect on the enzyme (103). Also, Skoog and Nordenskjold 
reported that the intracellular pool of dCTP following ara-c treat¬ 
ment is sharply decreased, implying that the inhibition of the kinase 
by dCTP does not block the conversion of ara-c to ara-CTP (142). 
Since ara-CTP has been shown to be the active form of the drug, 
the product of deoxycytidine kinase, ara-CMP, undergoes two additional 
phosphorylations which have been reported to be catalyzed by deoxy- 
cytidylate kinase and nucleoside diphosphokinase respectively (109, 
152). 
The subject of the mechanism of action of ara-c is a coup lex 
and confusing one. However, most theories are based on evidence 
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of the cell. DNA replication in whole mammalian cells (55, 75, 
143), tumor cells (31, 39, 70, 82, 84), and DNA viruses (20) is inhib¬ 
ited by ara-c. This body of evidence for DNA synthesis as a target 
area for the action of ara-c requires explanation at a more funda¬ 
mental level. Three major lines of evidence have been pursued to 
approach this: 1) study of the kinetic properties of DNA polymerases; 
2) studies of the incorporation of ara-c into nucleic acids; 3) 
studies of chromosomal damage, which may represent the morphologic 
manifestation of other mechanisms. 
As background to the discussion of the specific effects of 
ara-c on DNA synthesis, let us briefly characterize the cell's 
different DNA polymerase enzymes. The subject of mammalian DNA 
polymerases including the presentation of a standard nomenclature 
has recently been reviewed by Bollum (11). Four distinct mammalian 
enzymes have been designated: ,/3 ,2T, and mitochondrial polymerase. 
The qc polymerase (maxi polymerase, replicase, polymerase I, and 
polymerase A) is a high molecular weight (>130,000) cytoplasmic 
piotein and is responsible for the majority of DNA synthesis asso¬ 
ciated with replication. Consistent with this role, the enzyme 
concentration rises sharply in S-phase (28), it is stimulated by 
unwinding proteins and it may be able to use RNA pieces as an initia¬ 
tor (27). N-ethylmaleimide is a specific inhibitor of the poly¬ 
merase (11). 
The/3 polymerase(mini polymerase, polymerase II, polymerase B, 




found in both the cytoplasm and nucleus (26) Levels of this enzyme 
remain constant throughout the cell cycle and it has been presumed to 
be involved in post-replication repair (160). The polymerase 
(R DNA polymerase) accounts for a minor fraction of DNA polymerase 
activity (^ 1%) and its role in cellular replication is unknown 
(146). The mitochondrial polymerase also accounts for less than 1 
percent of the polymerase activity and function is presumed to be 
limited to synthesis of mitochondrial DNA (72, 99). 
Most of the research on the interaction of ara-c and DNA poly¬ 
merases predates the techniques for separating these different en¬ 
zymes. Therefore, hypothetical mechanisms of action of ara-c were 
based on studies using crude polymerase extracts. 
The competitive inhibition of DNA polymerases has been proposed 
to explain the cytotoxicity of ara-c. Many authors have reported 
inhibition of crude extracts of DNA polymerases by ara-c. This in¬ 
hibition was found to be due to ara-c's competition with deoxycy- 
tidine triphosphate (dCTP) as a substrate for DNA polymerases from 
partially purified extracts of calf thymus (52, 101) or from Walker 
256 Carcinosarcoma (51), with lysates of mouse L cells (55), and 
mouse lymphoma cells (106) and with crude reverse transcriptase prepa¬ 
rations from Raucher Leukemia Virus (106, 154). The Ki's for ara-c 
reported in these studies were reasonably low, suggesting that this cyti- 
dine analog might inhibit this reaction within intact cells. Further 
evidence for the competitive nature of this inhibition has been 
reported by Furlong (51) who demonstrated that ara-CTP did not inhibit 
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incorporation of thymidine triphosphate into DNA synthesized on an 
artificial template, poly dA-T. Since normal rules of base pairing 
preclude dCTP incorporation into such a molecule, and ara-CTP did 
not block DNA synthesis, it was concluded that ara-c's interference 
with polymerase function was limited to competitive binding at the 
dCTP site. The cause and effect relation between the competitive 
inhibition of the pofymerase and cell death has not adequately been 
demonstrated. 
The cytocidal effect of ara-c has been suggested to result from 
a state of unbalanced growth caused by inhibition of DNA synthesis 
while initially little effect of ara-c on RNA and protein synthesis 
occurs (143). Experiments reported by Graham and Whitmore (55) 
attempted to elucidate the connection between cell death and polymerase 
inhibition and to refute the theory of unbalanced growth. Studies 
on mouse L-cells showed that 3.6 X lCT^M ara-c inhibited DNA synthesis 
by more than 97% and that these cells underwent "unbalanced growth" 
for periods greater than one generation (24 hours) without necessarily 
losing viability. However, at a concentration of 7-2 X lCT^M for 
2 hours, there was an irreversible loss of viability sufficient to 
kill all S-phase cells. These authors concluded that unbalanced 
growth was not responsible for cell death and that if massive inhibi¬ 
tion of DNA synthesis was to be implicated, a mechanism had to be 
proposed whereby preservation of a relatively small amount of DNA 
synthesis, as little as 3l of the normal rate, can prevent loss of 
viability. Such a mechanism will be discussed below along with the 
10 

selective effects of ara-c on different cellular DNA polymerases. 
There have been numerous reports which apparently contradict 
the proposal that competitive DNA polymerase inhibition is causally 
related to cell death. Several investigators (31, 84, 165) have 
demonstrated that cell damage induced by high doses of ara-c either 
is not reversed or only partially reversed by dCTP. An irreversible 
component of ara-c's action was clearly shown by Karon and Shirakawa 
(75). After Don C cells were treated with 10 jug/ml of ara-c for 
24 hours, 80-90% of the cells remained viable as demonstrated by try¬ 
pan blue exclusion. However, when these cells were washed and re¬ 
suspended in drugfree medium, only 10% of the cells were viable by 
cloning. Therefore, despite removal of the drug, ara-c had already 
caused an irreversible change. 
Momparler's studies on the interaction of ara-c and fluorodeoxy- 
uridine (FUDR) raised yet more doubts as to the role of polymerase 
inhibition in cell death (102). Fifty percent of S-phase HeLa cells 
treated with 1 X ICT^m ara-c for 1 hour were killed. But a subse¬ 
quent 1 hour treatment with a sublethal dose of FUDR completely 
rescued the cells from ara-c toxicity. Since FUDR is also an S- 
phase specific DNA synthesis inhibitor (6l), an additive effect with 
ara-c on cell kill and DNA synthesis was anticipated. Although the 
basis for the observed antagonism is unknown, this study further 
suggested that cytotoxicity of ara-c is not adequately explained by 
inhibition of DNA synthesis. These results have been confirmed by 
other investigators (57)* In view of the poor correlation of ara-cTs 
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cytotoxicity with its competitive inhibition of DNA polymerases, 
other known effects of ara-c will be explored in order to further 
clarify the subject. 
There are several reports that indirectly support the hypothesis 
that the acute cytotoxic effect produced by ara-c results from its 
incorporation into DNA. First, H^ara-c has been shown to be incor¬ 
porated into DNA of various mammalian cells (29, 31, 37, 39, 56, 
143, 166). Second, purified mammalian DNA polymerases can catalyze the 
incorporation of H^ara-CTP into DNA in vitro (51, 100, 101). The 
incorporated radioactivity has been chronratographically proven to be 
ara-c (31, 37, 166). Third, short exposures of mammalian cell to 
ara-c have been shown to be mutagenic (69). 
Despite such evidence that ara-c is incorporated into DNA, the 
mechanism of this presumed highly toxic effect needs to be clarified. 
One possibility is terminal incorporation of ara-c into DNA with 
cessation of chain growth. This could be a serious lesion and in fact 
this chain defect was observed by Momparler using DNA extract from 
calf thymus (100, 101). However, this observation was not confirmed 
using DNA polymerase extracts from Walker Carcinosarcoma or in whole 
mammalian cells (31, 56). In both systems ara-c was incorporated 
into internal nucleotides exclusively. 
The discrepancy between these studies might be explained by the 
reported presence in thymus extracts of an unusual DNA polymerase, 
terminal transferase (10). This enzyme, found only in the thymus and 
leukemic cells, catalyzes the elongation of preformed oligomeric 
12 
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or polymeric DNA chains by adding deoxyribonucleoside monophosphates 
to the 3'OH ends of these chains (53). Terminal transferase is 
unlike any other known DNA polymerase in that it does not use nucleic 
acid templates for instruction (10). Therefore, the absence of a free 
3'OH group on a strand of DNA results in chain termination since the 
polymerase cannot skip to another region of the template and continue 
operations. Consequently, ara-c’s lack of an available 3'OH group 
might cause chain termination in the terminal transferase reaction but 
not necessarily with other polymerases, which function with a tem¬ 
plate. One could speculate that ara-c induced chain termination 
in the presence of terminal transferase could be the basis for the 
selective toxicity of ara-c for leukemic cells. Although this hypo¬ 
thesis is attractive, there are no studies that demonstrate such an 
effect; therefore, other lines of evidence must be considered. 
One could assume that if the incorporation of ara-c into DNA 
represents the cytotoxic lesion, the rate of incorporation would be 
proportional to cell lethality. Such a correlation was not observed 
in studies by Graham and Whitmore or Chu (30, 56). Chu demonstrated 
that when murine leukemia L5178Y cells were exposed to 3«3 X lCT^M 
ara-c, incorporation of H^ara-c into DNA stopped at 1 hour, although 
cell lethality continued to increase. However, the high dose of ara-c 
used could have blocked its own incorporation by inhibiting the poly¬ 
merase completely. But, since the higher dose of ara-c is associated 
with increased cell death and the incorporation of ara-c into DNA 
is dependent on a functional polymerase, for which high dose ara-c 
13 
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is a potent inhibitor, a new hypothesis would have to be proposed 
to reconcile this apparent contradiction. 
The discrepancies in the above discussion could be explained 
by assuming that the high dose of ara-c potentiates the cytotoxicity 
of the ara-c already incorporated into DNA by inhibition of its 
excisional repair. A differential sensitivity to ara-c for the re¬ 
pair and replicative function of the polymerases was first suggested 
by Cleaver (35) s who demonstrated that the repair of ultraviolet- 
induced lesions in HeLa cells containing DNA substituted with 5- 
Bromouracil was not inhibited by ara-c. There is precedent for this 
selectivity of ara-c in other eukaryotic and prokaryotic cells. 
In E. coli, three distinct DNA polymerases have been isolated 
and designated: I, II and III (151). The function of polymerase I 
has been implied from studies of E. coli Pol A1 mutant in which this 
enzyme is lacking (126). Since these cells replicated normally 
except for increased sensitivity to ulatraviolet-induced damage, 
polymerase I has been presumed to be responsible for DNA repair (126). 
Polymerase II has been proposed to be the replicase, and consistent 
with this function in mammalian cells, its activity is potentiated 
by unwinding proteins (126). Rama Reddy et al. have reported that 
the replicase (polymerase II) is sensitive to inhibition by ara-c 
while the repair enzyme (polymerase I) is resistant (126)., This 
finding has been confirmed by others (151). A similar observation 
was made by Winterberger in studying the simple eukaryotic organism 
yeast (l6l). The replicase, as In E. coli, was more sensitive to 
ara-c than the putative repair enzyme. 
14 
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The differential sensitivity of various DNA polymerases has also 
recently been reported in mammalian cells (45, 90, 91, 137, 149). 
Lynch et al. was able to separate two distinct polymerases from iso¬ 
lated hepatocyte nuclei. The first was a high molecular weight (7.IS) 
protein that showed a marked increase in concentration associated with 
the rise in DNA synthesis induced by partial hepatectomy or thyroid hor¬ 
mone infusion (90, 91). These properties are consistent with the 
mammalian replicase, polymerase °C . Since the second hepatocyte 
polymerase is a low molecular weight (3.2S) protein that is able to 
repair single strand breaks in DNA induced by bleomycin (132), it 
resembles the mammalian DNA repair enzyme, polymer as q/3 . Stenstrom 
et al. using isolated hepatocyte nuclei were able to demonstrate 
that the replicase, polymerase, is 1000-fold more sensitive to 
ara-c than is the repair enzyme, polymerase/9 (45, 149). Lynch 
et al. (91) have confirmed these findings using the same system. 
However, when normal human lymphocytes were analyzed, the Ki of 
polymerase/9 for ara-c was only five-fold lower than that of poly¬ 
merase csi. (137). Although in varying degrees, in all cell lines 
investigated to date, the replicase seems to be more sensitive to 
ara-c than is the repair DNA polymerase. Furthermore, this differential 
effect suggests a mechanism of action for ara-c which includes both 
the previously documented inhibition of DNA synthesis and the incor¬ 
poration of this analog into DNA. One could speculate that high levels 
of ara-c are necessary to inhibit the repair enzyme which otherwise 
would excise the ara-c incorporated into DNA by the replicase. 
15 
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A possible microscopic correlation of the molecular damage 
caused by the cell’s inability to repair incorporated ara-c lesions 
is the appearance of chromosomal abnormalities. Ara-c can produce 
marked chromosomal aberration in mammalian cells with chromatid 
breaks and extensive fragmentations (5-7, 74, 8l). Karon et al. 
(74) showed that ara-c cytotoxicity correlated very well with the 
number of chromosome breaks produced, five or more breaks per metaphase 
being lethal to the cell. The interference of ara-c with chromosomal 
integrity as a consequence of inhibition of DNA synthesis and repair 
would require that the cytotoxicity of ara-c be limited to cells rap¬ 
idly incorporating DNA. 
Ara-c is a cycle-dependent agent effective only in S-phase, 
which is the period of DNA synthesis in the cell cycle (55? 75} 82, 
165). This S-phase specificity is due to the inhibitory effect of ara-c 
on DNA replication and to an increase in the phosphorylation of ara-c 
which results from an S-phase increase in deoxycytidine kinase acti¬ 
vity (103). Preceding S-phase is G-^ phase during which the cells 
are spared the cytotoxic effects of ara-c. 
Several investigators have noticed that ara-c can block the 
movement of G-^ cells into S-phase; thus, this drug can be self-limiting 
with respect to its cytotoxic activity (1, 55 > 153)- Although others 
have not observed a G-^/S block (76), the observation that ara-c 
induced partial cell synchronization strongly supports this effect 
(1, 8, 42, 85, 127, 159s 164). Consequently, cells collected near 
the Gj/S boundary could rapidly resume cell cycle traverse as a 
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synchronous cohort after ara-c is removed (1, 8, 42, 85, 127, 159, 164). 
Other impIdeations of S-phase specificity will presently be discussed. 
As it is with DNA, ara-c is also incorporated into RNA (29, 30, 
33, 37)* However, since ara-c causes only minimal impairment of 
general cellular RNA synthesis at doses that are inhibitory to DNA 
synthesis (36, 55, 108, 165), an effect on a specific RNA might be 
obscured. In fact, when RNA was fractionated, ara-c was not incor¬ 
porated into high molecular weight rRNA (166) or tRNA (139) but was 
predominantly present In low molecular weight mRNA (30). Further¬ 
more, Chu (30) has demonstrated that the cytotoxicity of ara-c cor¬ 
relates only with this analog's incorporation into low molecular 
weight mRNA. Even though mRNA is synthesized throughout the cell 
cycle (120, 155), and even though ara-c is S-phase specific, the 
cytotoxicity of ara-c could still result from an interaction with a 
specific S-phase mRNA. One type of S-phase specific protein is 
histones, which is a nuclear protein that Is necessary for the assemb¬ 
ly of the newly-formed DNA complexes (131)- Histone synthesis requires 
a specific S-phase 7-9S mRNA(histone messenger) and Borun et al. 
demonstrated selective inhibition of histone messenger and histone 
synthesis by ara-c (12, 135). After treatment with actinomycin D 
and ara-c, both histone synthesis and the amount of 7-9S RNA (histone 
messenger) associated with polysomes declined four times faster than 
after exposure to actinomycin D alone. Since actinomycin D is known 
to block RNA transcription, ara-c's interference must occur after 
transcription to account for the rapid decay when synthesis of his¬ 
tone messenger is no longer occurring. Furthermore, one could 
17 

speculate that Incorporation of ara-c into mRNA results In either 
accelerated metabolism of mRNA or in interference with translation. 
The preceding argument strongly supports the theory that ara-c 
incorporation into mRNA Is a mechanism of action of this drug. How¬ 
ever, this hypothesis does not mitigate the importance of ara-c’s 
inhibition of DNA polymerase or its incorporation into DNA. All of 
the aforementioned modes of action of ara-c could coexist, thereby 
explaining the potent cytotoxic nature of this compound. 
There is yet another hypothesized locus of action for ara-c 
which, however, has been refuted by many investigators. Initial 
studies on the mechanism of ara-c cytotoxicity led to the sugges¬ 
tion that the drug produced inhibition of DNA synthesis as a consequence 
of the inhibition of the reduction of CDP to dCDP by the enzyme ri¬ 
bonucleotide reductase (31)- However, when Skoog and Nordenskjold 
(142) measured nucleotide pools, ara-c caused only a transient de¬ 
crease in the dCTP pool. In addition, when ribonucleotide reductase 
was assayed directly, ara-CTP produced a weak inhibition (73, 105), 
thereby suggesting that the inhibition of the reductase is not of 
significant consequence at the intracellular drug levels usually reached. 
Having discussed some of the proposed mechanisms of action of ara-c, 
it is important to consider the implications of these theories in the 
clinical application of the chemotherapeutic agent. 
The clinical efficacy of ara-c as an antineoplastic agent is 
profoundly affected by the schedule of administration and dosage of 
this agent. After intravenous injection, ara-c is rapidly deaminated to 
18 
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ara-u, uracil arabinoside (41). The plasma half-life for ara-c is 
biphasic with an initial fast phase (mean half-life 12 minutes) and 
a slower second phase (mean half-time 111 minutes) (65). In addi¬ 
tion, Ho and Frei (65) demonstrated that the plasma half-life is 
independent of the dose; therefore, higher doses correlated with higher 
plasma levels of ara-c. 
Since ara-c is S-phase specific and only a small percentage of 
tumor cells are in S-phase at a particular time, low dose continuous 
infusions have been commonly employed to expose a higher percentage 
of cells to ara-c during their vulnerable period (49). Yet, the 
efficacy of intermittent bolus therapy with appropriate dose intervals 
has also been demonstrated (110). The interval required for maximal 
cell kill correlates well with the time necessary for recovery of 
DNA synthesis following ara-c (110, l4l). This observation suggests 
that ara-c synchronizes cells in early S-phase, and upon recovery 
these cells progress to another part of S-phase where they are sensi¬ 
tive to a second dose of ara-c (85, 110, l4l). Recalling the pre¬ 
vious discussion of the dose dependence of the mechanism of action 
of ara-c, it is therefore possible that large bolus doses could be 
acting at different sites and be as effective as prolonged low dose 
infusion. 
If the cell kinetics of the tumor cells differ from that of the 
host tissues, use of an intermittent dose schedule could improve the 
therapeutic index of ara-c by decreasing host toxicity. For the 
treatment of acute leukemia, many clinical protocols employing inter¬ 
mittent doses or continuous infusions of ara-c have been tested. 
19 
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Numerous protocols for the treatment of acute myelogenous leu¬ 
kemia (AML) have employed ara-c alone or In combination chemotherapy. 
Although these protocols differ widely in design, only the outcome of 
the most promising ones will be discussed as a standard of comparison 
for proposed new combinations. When used as a single agent for the 
treatment of adults with AML, ara-c has induced complete remission 
in approximately 25 percent of the patients (9, 5*0- A remission 
rate of 65 percent has been achieved by the combination of ara-c and 
thioguanine given every 12 hours until marrow hypoplasia resulted 
(34). In addition, the combination of a four-day course of daily 
ara-c with daunorubicin on day 1 induces complete remission in over 
50 percent of patients with AML (110). A greater than 50 percent 
remission rate was also achieved with a complicated protocol involving 
ara-c, vincristine, prednisone and cyclophosphamide (150). 
Ara-c has also been tried in the treatment of acute lymphocytic 
leukemia (ALL). However, since only one-third of patients with 
ALL achieved either a complete or partial remission with ara-c (144) 
and other agents are significantly more effective, the use of ara-c 
in ALL is limited to patients resistant to standard therapy. 
L-Asparaginase 
Since the original discovery of a tumor inhibitory factor in 
guinea pig serum by Kidd (64) and its identification as asparaginase 
by Broome (16), this enzyme has been shown to be tumoricidal to 
selected rodent (16, 80), canine (64;, 113) and human (66) neoplasms. 
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Although asparaginase has been isolated from a wide variety of sources, 
the bacterial enzyme from E. coli is most often used clinically and 
for investigation (15, 116). 
E. coli asparaginase (EC-2) is a 127,000 molecular weight protein 
that catalyzes the hydrolysis of asparagine to aspartic acid and 
ammonia (15, 17, 24, 37, 66, 95). In addition, as an inherent property 
of the enzyme, it has a small amount of glutaminase activity, which 
catalyzes the conversion of glutamine to glutamic acid and ammonia 
(116). Following the perenteral administration of asparaginase, 
plasma asparagine rapidly falls to undetectable levels (17, 24, 37, 
66, 95, 130) and there is also a delayed transient decrease in glutamine 
(116). 
The consequences of asparagine deprivation are the result of 
its important role in cellular function. The major metabolic use 
of asparagine is as one of the required animo acid constituents of 
proteins (24, 47, 95, 96, 147, 163). However, since most cells are 
capable of de novo biosynthesis of asparagine by the enzyme asparagine 
synthetase (16, 66, 122), asparagine is not an essential nutrient 
for mammalian cells (16, 17, 24, 116). In 1956, however, Neuman 
and McCoy (111) demonstrated for the first time a cell line. Walker 
Carcinosarcoma 256, which in contrast to normal mammalian cells has 
a nutritional requirement for asparagine. This finding has since been 
confirmed and extended to a limited group of tumor cells (15-17, 
24, 58, 66, 92, 96). In fact, tumor cells that require exogenous 
asparagine as expected have either low or absent levels of asparagine 
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synthetase (17, 62, 119, 122). Furthermore, cells that require 
asparagine are susceptible to the lethal effects of asparaginase 
(17, 62, 66, 118, 119, 122) and the development of asparaginase 
resistance is associated with increased levels of asparagine syn¬ 
thetase (17, 62, 66, 118, 119, 122). Therefore, one can conclude 
that the antitumor action of asparaginase is the result of asparagine 
depletion (17, 62, 66, 118, 119, 122). 
Although the mechanism of cell death following asparagine de¬ 
pletion has yet to be fully elucidated, the inhibition of protein 
synthesis following asparagine depletion or asparaginase has been 
well documented (24, 47, 89, 95, 96, 138, 147, 148, 163). One class 
of proteins that has a high asparagine content is glycoproteins 
(77)* The high asparagine content of these proteins is very sig¬ 
nificant in that the oligosaccharide chains are covalently bonded to 
asparagine residues (24). Since cell membranes have a high glycopro¬ 
tein turnover (14), and asparaginase inhibits glycoprotein synthesis 
(59, 71, 77), treatment with asparaginase could result in loss of 
membrane integrity (13, 14, 77, 78). Furthermore, such membrane 
damage would account for the observed rapid lysis of susceptible 
cells following asparaginase (43, 67). An alternate explanation of 
cell l^sis has also been proposed by Dod et al. (43) who showed that 
asparaginase could directly solubilize partially purified cell membranes 
in vitro. 
Aside from inhibition of glycoprotein synthesis, there are other 
important disruptings in cellular mechanisms induced by asparaginase. 
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Following the rapid inhibition of protein synthesis, there is a 
delayed inhibition of DNA (24, 47, 66, 89, 96, 148) and RNA (24, 
47, 66, 89, 96, 148) synthesis. The delay suggests that the decrease 
in DNA and RNA synthesis is secondary to the inhibition of protein 
synthesis (47, 66, 96, 148). 
The initiation of DNA synthesis requires the synthesis of special 
proteins (63, 121, 140). The inhibition of protein synthesis in late 
Gq phase results in the inhibition of the initiation of DNA synthesis 
and hence blocks the transition of cells into S-phase (50, 68, 117). 
Asparaginase, as an inhibitor of protein synthesis, would thus be 
expected to block the initiation of DNA synthesis, resulting in an 
accumulation of cells at the G^/S junction. In fact, an asparaginase- 
induced G-j/S block of cell cycle traverse has been reported by several 
investigators (86, 117, 136). However, a contradictory result was 
observed by Ernest (48), who demonstrated that asparaginase inhibited 
S-phase cells but did not block the G-^ to S transition. Finally, 
Paliardi et al. (115) were also unable to confirm an arrest of cell 
passage from G^ to S-phase. Albeit that the effect of asparaginase 
on the cell cycle is controversial, most investigators feel that this 
effect is of secondary importance in contrast to the previously dis¬ 
cussed independent lytic effect (48, 117). 
Other hypotheses for the mechanism of action of asparaginase, 
Welch are independent of its effect on protein synthesis, have been 
described. Wood et al. (162, 163) have proposed that asparagine, 
depletion, and therefore asparaginase, has a direct Inhibitory effect 
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on DNA synthesis by blocking de novo biosynthesis of pyrimidines. 
They demonstrated that C asparagine is incorporated into pyrimidines, 
suggesting a role for asparagine as a precursor for pyrimidine syn¬ 
thesis. Even though asparagine is not directly involved in pyrimi¬ 
dine synthesis (88), its conversion to a required precursor such as 
glycine could explain the incorporation of label into pyrimidines. 
Meister (98) has described just such a pathway for glycine synthesis 
from asparagine. Moreover, if asparaginase inhibits glycine synthesis, 
the effects of asparaginase should be able to be blocked by the 
administration of exogenous glycine. In fact, not only can glycine 
antagonize the effect of asparaginase (130) but plasma levels of 
glycine fall following treatment with asparagine (129), further 
supporting the requirement of asparagine in glycine and nucleotide 
synthesis. However, significant decreases in intracellular pyrimidine 
pools following asparaginase have yet to be demonstrated and therefore, 
the importance of asparaginase inhibition of pyrimidine metabolism 
and DNA synthesis cannot now be determined. 
Another site of action for asparaginase might involve the enzyme 
ribonuclease. An increase in ribonuclease, an enzyme that hydrolyzes 
RNA, has been proposed as a causal agent in the regression of murine 
lymphosarcoma P1798 (2) since only tumoricidal drugs including aspara¬ 
ginase caused this increase (2, 94, 97)- Although this does not suggest 
a specific mechanism of action of this drug, it provides evidence that 
asparaginase may share a common final pathway with other agents in 
the induction of lymphocytolysis. Although 15 years have passed 
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since Broome (16) identified asparaginase as the cytotoxic component 
of Guinea Pig Serum, the exact tumoricidal mechanism of this enzyme 
is still unknown. However, this has not prevented the successful 
clinical application of asparaginase in the treatment of acute leukemia. 
The clinical efficacy of asparaginase is almost entirely limited 
to the treatment of acute leukemia (24). Oettgen (112) has recently 
reviewed the clinical results of asparaginase therapy, alone and in 
combination with other drugs. The best responses to asparaginase therapy 
were in children and adults with acute lymphocytic leukemia. Of 
the 395 patients reviewed who were treated with asparaginase alone, 
214 achieved either a complete or partial remission (54%) (112). 
However, of the 200 patients with acute nonlymphocytic leukemia, 
including acute myelogenous, acute myelomonocytic and acute undiffer¬ 
entiated, only 21% had either complete or partial remissions with 
asparaginase therapy alone (112). 
Asparaginase in Combination Chemotherapy 
Although the use of several combinations of asparaginase with 
other cytotoxic agents have been reported to be synergistic in animals 
and/or man, only the combinations of asparaginase with ara-c or metho¬ 
trexate will be discussed here because of their direct importance 
to this thesis. Since ara-c and asparaginase are both useful drugs 
in the treatment of acute leukemia, and since they have different 
host toxicities (9, 54, 112), their combination is a logical choice. 
In fact, the combination of ara-c and asparaginase has been shown to 
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be more effective than either drug alone in the treatment of human 
and murine leukemias (4, 19, 46, 60, 87, 114, 124, 125). Although 
several trials have employed this combination in the therapy of acute 
lymphocytic leukemia (46, 60, 114, 125), there are no reports to my 
knowledge of such a trial in acute myelogenous leukemia. 
The first clinical trial of the combination of ara-c and aspara¬ 
ginase was conducted by Hardisty and McElwain (60) who reported 8 
complete remissions in 9 children with previously treated acute 
lymphocytic leukemia. The protocol consisted of using ara-c daily 
for 5-14 days followed by daily asparaginase for 9-28 days. The 
value of the sequential administration of ara-c, then asparaginase, 
was confirmed by Ekert et al. (46). They reported 8l% complete or 
partial remission in 17 children with acute lymphocytic leukemia, 
using an ara-c bolus every 8 hours for 4 days followed by 4 daily 
doses of asparaginase. Finally, sequential administration of ara-c- 
asparaginase was also shown to be synergistic in murine leukemia 
EARAD (19). In contrast, simultaneous treatment with both ara-c 
and asparaginase has been reported to produce in acute lymphocytic 
leukemia remissions rates of 6l% (15/24) and 68% (15/22) in two 
separate studies (114, 125). Simultaneous exposure in mice produced 
a synergistic response in the treatment of murine L5178Y when both 
drugs were administered in large doses on each of three separate 
days (4). Although all the reported protocols for the combination 
of ara-c-asparaginase resulted In an enhanced response rate as compared 
with asparaginase alone, the optimal schedule for the administration 
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of this combination has not yet been determined, but it is inves¬ 
tigated further in this thesis. 
For the treatment of murine and human leukemias, the importance 
of the schedule of administration of asparaginase with another S- 
phase specific DNA synthesis inhibitor, methotrexate, was first demons¬ 
trated by Capizzi et al. (22, 23, 25). They noticed that when mice 
with murine leukemia L5178Y were treated with asparaginase preceding 
methotrexate by less than 24 hours, there was an antagonistic response 
in mean animal survival time. However, when the order to the drugs 
was reversed and methotrexate preceded asparaginase, this antagonism 
was not observed. Furthermore, the subsequent treatment with as¬ 
paraginase also decreased methotrexate’s host toxicity and since 
the tumoricidal effect was not diminished, this regimen resulted 
in an enhanced therapeutic index. These results have been confirmed 
by other investigators (83, 156, 157). 
Since ara-c and methotrexate are both S-phase specific inhibitors 
of DNA synthesis, their similarity suggested that their interaction 
with the protein synthesis inhibitor, asparaginase, might be similar. 
Therefore, the studies of Capizzi et al. (22, 23, 25) on the combina¬ 
tion of methotrexate and asparaginase served as a basis for investigating 
whether the combination of ara-c-asparaginase also showed schedule- 
dependency. The purpose of this thesis is to determine the optimal 
schedule for the administration of ara-c and asparaginase and to 




Leukemic Cell Lines 
All animal and tissue culture studies were performed with the 
L5178Y/asn“ murine leukemic cell line. These cells require asparagine 
for growth and therefore are sensitive to asparaginase (4, 58, 134). 
In addition, these cells are also sensitive to ara-c in vivo and in 
vitro (4, 32, 33). 
Stock lines of L5178Y were maintained in vivo as an ascites tumor 
in 20-25 gram female mice (Jackson Laboratories, Bar Harbor, 
Me.). The tumor was transferred at weekly intervals into new mice 
by intraperitoneal injection of 10^ cells. For in vitro studies, 
stock lines of L5178Y were maintained as liquid suspension culture in 
Fisher’s medium supplemented with 10$ horse serum (designated FS^ 
and purchased from Grand Island Biological, New York) and were kept 
in continuous logarithmic growth by frequent subculturing. Fisher's 
medium was protected from light by wrapping the bottles in aluminum 
foil in order to prevent the formation of toxic photoxidation products 
(3, 150). All cultures were maintained at 37° C, in a 5% CO^ incu¬ 
bator and under these conditions, these cells had a mean doubling time 
of 8.5 hours. 
In Vivo Tumor Growth Curves 




tumor cells in a volume of 0.1 ml diluted in sterile normal saline 
(NSS). On day 3, animals were treated with either ara-c 1000 mg/kg 
(Upjohn, Kalamazoo, Mich.), asparaginase 500 IU/kg (Merck, Sharp and 
Dome, Pa.) or normal saline. The drugs were freshly prepared from 
sterile powder in normal saline and the final injection volume was 
0.1 ml. At various intervals, two animals were sacrificed by cervical 
dislocation. The skin over the peritoneum was opened and the peri¬ 
toneal cavity was lavaged with three 5 ml aliquots of heparinized 
normal saline (0.5 IU/ml) to collect the tumor cells. After dilution with 
NSS and the addition of 3 drops of Zapisoton (Coulter Electronics, 
Hialeah, Fla.) to lyse the red cells, the tumor cells were counted in 
a Model A Coulter counter (Coulter Electronics, Hialeah, Fla. 
Tnis counter was used for all experiments in this thesis). Results 
were expressed as total cells per animal. 
Animal Survival Studies 
Six groups of 6 mice were segregated into separate cages and 
oJ 
inoculted with tumor and treated with drugs that were prepared as 
A 
described above. The treatment schedule is described in Table 1. 
As an indication of drug toxicity, each group of animals was weighed 
daily until they regained their pretreatment weight and there were no 
deaths due to drug toxicity in any of these studies. Results were 
expressed as mean animal survival in days following tumor injection 
and 60 day survivors were considered cured. 
29 

In Vitro Cell Viability 
Thirty-five ml of L5178Y cells in log phase growth at a concen- 
5 
tration of 1-3 X 10 cells/ml were treated with 1 ml of a drug freshly 
prepared in NSS according to the treatment schedule in Table 2. Pre- 
and post-treatment cell counts were determined in a Model A Coulter 
Counter after a 1:10 dilution with NSS. Following an 8-hour drug 
exposure, the cells were washed three times by centrifuging them for 
10 minutes at 1000 rpm in a Sorvall GLC-2 centrifuge (Dupont Indus¬ 
tries, Newtown, Conn.) in a 37° room and then resuspending the cells in 
35 ml of drug-free FS^ by gentle pipetting. One hour and thirty 
minutes after concluding the first centrifugation, the cells were 
treated a second time as diagrammed in Table 2. At the conclusion 
of a second 8-hour exposure, the cells were again counted and washed 
as above and viability was determined by a slight modification of 
the soft agar cloning technique described by Fisher and Chu (32). 
In contrast to the 60 cells/tube used by Fisher and Chu, the inoculum 
used in these experiments was either 100 and/or 200 cells per tube 
depending upon the anticipated cell kill. Cloning efficiency varied, 
the mean being 75% and the data was therefore normalized and expressed 
as percent of control cloning efficiency. 
A sequence of experiments was undertaken to determine if the 1 
hour and 30 minutes between treatments was critical. The four time 
intervals tested were as follows: a) 1 hour overlap b) 1 hour 
thirty minutes c) 4 hours d) 8 hours. In group A the second drug 
was added 1 hour prior to the conclusion of the first treatment and 
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was therefore included in the FS-^q used in washing. The treatment 
schedule is diagrammed in Table 3- 
In Vitro Growth Curve Following Ara-c Pretreatment 
L5178Y cells in culture were treated with either ara-c (final 
concentration 10~^ M) or normal saline for 8h hours as described 
above for the first treatment of the in vitro viability studies. 
Following the resuspension of the cells after the third wash, hourly 
cell counts in duplicate were measured by diluting 1 ml of cells with 
9 ml of NSS. Prior to counting, the diluted cell suspensions were dis¬ 
persed with a pasteur pipette. A graph of cell concentration as a 
function of time post-wash was used to express these results. 
Incorporation of TdR into DNA 
L5178Y cells in culture were pretreated as described above for 
the in vitro growth curve. Following the third wash the cells were 
resuspended in FS-^q to a final concentration of 3-6 X 10 cells/ml. 
One ml of cell suspension was then placed in a sterile, stopperred, 
10 ml Erlenmeyer flask that already contained either 0.1 ml of normal 
saline solution or 0.1 ml of asparaginase (6 IU/ml prepared in NSS). 
Following a 1 hour preincubation at 37° C in a Metabolyte shaking 
water bath (New Brunswick Scientific Company, New Brunswick, N.J.), 
0.1 ml of H deoxythymidine (1 uc of H methyl TdR diluted in Fisher's 
medium. Specific activity 2.0 C/rrM from New England Nuclear, Boston, 
Ma.) was added to the incubation mixture. At 10 minute intervals 
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for the next 1 hour, 0.1 ml of the mixture was removed and applied to 
a glass fiber disc (2.4 cm GF/A Whatman filter) which had been pre¬ 
treated with 0.2 ml of 0.5 M NaOH and allowed to dry. At the conclu¬ 
sion of the incubation, the discs were dried under a heat lamp and placed 
on Whatman #1 filter paper in an 18 cm Buchner funnel mounted on a 
suction flask. Up to three layers of discs, separated by Whatman #1 
filters were washed with ten 100 ml aliquots of ice cold 5% trichloro¬ 
acetic acid (TCA) followed by four 100 ml aliquots of 95% ethanol 
and then four 100 ml aliquots of acetone. The discs were again dried 
and then transferred to scintillation vials with 10 ml of Econofluor 
(New England Nuclear, Boston, Ma.). The samples were counted in a 
Packard Tricarb Liquid Scintillation Counter (Packard Electronics). 
The rate of incorporation of H TdR into DM was calculated using 
linear regression analysis and the results were expressed as dpm/10^ 
cells/minute of incubation. 
An alteration of this general method was used when it was desirable 
to determine DM synthesis within 1 hour post-ara-c treatment. For 
these experiments, the cells were divided into two groups, half was 
washed with FS1Q plus asparaginase (0.5 IU/ml) and the other group with¬ 
out asparaginase. Also to accomplish the removal of the drug within 1 
hour, the washing was reduced to three 7 minute centrifugations. 
At 1 hour 1 ml of cells was placed in a 10 ml flask and 0.1 ml of H 
TdR was immediately added since the 1 hour wash with asparaginase 






H Ara-c Incorporation Into Macromolecules 
TWo ml of 1-2 X 10 ^ L5178Y cells in FS10 were added to a 10 ml 
sterile, stopperred ErTenmeyer flask that contained 0.2 ml of H 
ara-c (5 uc of specific activity 13-2 mc/nM. Prepared in Fisher’s 
medium and purchased from New England Nuclear, Boston, Ma.). In 
order to determine if asparaginase inhibited ara-c's incorporation into 
DNA and/or RNA, six flasks of cells were treated as follows: two of the 
flasks received 0.1 ml asparaginase (12 IU/ml) initially, two others 
received 0.1 ml of asparaginase (12 IU/ml) after 2 hours and the re¬ 
maining two flasks received 0.1 ml of normal saline. Every thirty 
minutes for 4 hours, 0.2 ml of the mixture was removed and spotted 
on glass fiber discs that were previously treated with both 0.2 ml of 
-4 
0.5 M NaOH and 0.2 ml 10 M cold ara-c. The discs were then washed 
and counted as described above for TdR. 
H Leucine Incorporation into Protein 
Cells were prepared as previously described for TdR but received 
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0.1 ml H Leucine (2 uC of 4,5H leucine specific activity 5 C/mM 
purchased from New England Nuclear, Boston, Ma.). The 0.1 ml aliquots 
were pipetted into 3 nil of ice cold 10% Trichloroacetic acid and the 
samples were processed and counted by the method described by Rosenfelt 
(128). 
Autoradiography and Mitotic Index 
One ml of 2 X 10^ L5178Y cells was placed in a stopperred, sterile, 
10 ml Erlenmeyer flask with 0.1 ml UdR (1 uc of 25 C/mM 5,H^ from 
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New England Nuclear, Boston, Ma.) and 0.1 ml colcemid (final concen¬ 
tration 0.05 ug/ml from Grand Island Biological, New York). At the 
conclusion of a 1 hour Incubation, the cells were washed two separate 
times with 3 nil of cold normal saline and then resuspended in 2 drops 
of horse serum. After the slides were prepared and dried, they were 
fixed for 15 minutes in absolute methanol. The slides were developed 
by the method of Durie and Solomon (18) with the exception that after 
dipping them in the emulsion they were not redipped into scintillation 
fluid and consequently exposure time was increased to 4 days. The 
autoradiograms were stained with Geimsa and Wright stain and 500 cells 





Results and Discussion 
The design of a chemotherapeutic protocol for the use of aspara¬ 
ginase plus ara-c should be guided by the pharmacology of the individual 
agents as reviewed above. Although it is inpossible to predict a 
priori the interactions that will occur, an initial hypothesis can 
be based on known cytokinetic effects. Since ara-c is an S-phase 
specific agent (55, 75, 82, 165) which is therefore most effective 
against rapidly dividing cells, an additive or synergistic response 
might be expected to occur if cells were treated with ara-c shortly 
after they were released from the inhibition of asparaginase which 
has been reported to cause a G^/S block (86, 117, 133)- To explore 
this hypothesis, a preliminary group of experiments was necessary 
to determine when L5178Y cells recover from asparaginase toxicity 
in vivo. Therefore, a tumor growth curve in mice following aspara¬ 
ginase was determined as described above. The pooled data of two 
experiments is presented in Figure 1. After a single injection of 
asparaginase, there is a greater than one log cell kill followed by a 
plateau of cell number for 4 days. Between 120 and 144 hours post¬ 
treatment, the remaining tumor cells resume logarithmic growth. A 
similar observation has been previously reported by Rosenfelt (128). 
Consequently, one of the treatment regimens tested in mice was the 























Figure 1:Effects of 500 IUAg of Asparaginase upon the total number 
of ascites cells per mouse. Data points represent the pooled re¬ 
sults of two experiments. ( )=number of animals per time point 
and the point is the mean of those animals. 
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then 120 hours later a single bolus of ara-c was administered. 
Another Initial hypothesis was based on a presumed asparaginase- 
induced G./S block (86, 117, 133) which has been suggested to result 
from the inability of the cell to initiate DNA synthesis in the absence 
of protein synthesis (63, 121, 140). In addition, recovery from the 
DNA synthesis inhibitor, ara-c, probably requires de novo synthesis of 
certain proteins. Therefore, it might be optimal to treat cells 
with asparaginase just prior to their resumption of DNA synthesis 
while in the process of recovering from ara-c. Under these conditions, 
asparaginase might block cells from recovering from ara-c’s toxicity. 
To determine the appropriate treatment interval, an in vivo tumor 
growth curve following ara-c was determined as described above and is 
presented in Figure 2. This growth curve implies that the cell number 
increases rapidly after 144 hours and it is thus likely that most re¬ 
maining cells begin to recover approximately 120 hours after ara-c. 
Therefore, in the design of a trial treatment schedule, asparaginase 
followed ara-c by 120 hours. 
Finally, the third schedule of the combination of ara-c and 
asparaginase tested was the simultaneous treatment with both drugs on 
day 3- This was selected because it has been reported to be clinically 
useful (114, 125) and also to serve as a control for the other pro¬ 
tocols . 
The treatment schedules and results of the animal survival studies 
are presented in Table 1. Treatment with ara-c alone prolonged the 
























Figure 2: Effect of 1000 mgAg of ara-c upon the total number of 
ascites cells per mouse. Data points represent the results of 
one experiments. ( )=number of animals per time point and the 
point is the mean of those animals. 

Table I 
Effect of different treatment schedules on mean survival time and 
the number of animals cured following IP injection of 10° tumor 
cells on day 0. All drugs delivered in 0.1 ml. Asparaginase= 500 
IU/kg. Ara-c = 1000 mg/kg. The results are expressed as Mean 
Survival + standard deviation and represent the pooled data from 








I Saline 10.1 + 1.7 0/46 
II AsnT ase 2.6.4 + 1.8 0/34 
III Ara-C 21.0 + 2.7 3/24 
IV Asn’ase + 
Ara-c 
18.1 + 1.8 1/24 
V Asn’ ase Ara-C 21.9 + 4.3 1/24 
VI Ara-C Asn' ase 30.3 + 0.9 20/24 
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asparaginase alone cured none of the animals and although it prolonged 
the life of all animals, asparaginase was slightly less effective than 
ara-c alone. When animals were treated simultaneously with both drugs 
or when asparaginase preceded ara-c by 120 hours, animal survival was 
equivalent to ara-c alone. However, when ara-c preceded asparaginase by 
120 hours, there was a marked synergistic response with 83% (20/2*1) 
of the animals being cured. In addition, there were no toxic deaths 
and the maximum weight loss in any group was 10%. These experiments 
demonstrate a schedule-dependent synergistic protocol for the treat¬ 
ment of mice carrying L5178Y leukemia and this protocol has minimal 
host toxicity as measured by weight loss. 
The effect of the combination of ara-c and asparaginase on animal 
tumor models has been reported by other investigators (4, 19). In 
contrast to the results of this study, Avery and Roberts observed 
that the simultaneous treatment of L5178Y bearing mice with these two 
drugs on each of three days (day 1, 4, and 7) cured 36 of 43 mice 
(146). Furthermore, three doses of ara-c alone cured none of the an¬ 
imals, and three doses of asparaginase cured only 3 of 15 mice. Even 
though the drug doses used by Avery and Roberts for each injection were 
similar to those employed in this study, their use of multiple doses 
and short intervals between doses complicates the comparison of these 
two experiments. In addition, based on the studies of Avery and 
Roberts it is difficult to separate the interaction of the simul¬ 
taneous administration of both agents from the effects of either 
drug with a subsequent dose. In fact, the synergism observed by Avery 
and Roberts may actually support the advantage of the sequential 
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administration of ara-c and then asparaginase if as a consequence 
of multiple doses, asparaginase is enhancing the effect of a previous 
dose of ara-c. The superiority of the sequential regimen is further 
supported by an animal survival equivalent to that reported by Avery 
and Roberts for the studies reported here despite a larger tumor 
burden at the time of initiating therapy. The animals used here had 
a larger tumor burden since treatment was initiated on day 3 in con¬ 
trast to the mice used by Avery and Roberts which began receiving 
therapy on day 1. The delay of therapy to day 3 results in the mice 
having at least one log more cells than on day 1, thereby increasing 
the difficulty of curing the animals (158). 
A synergistic increase in animal survival for the combined use 
of ara-c and asparaginase in treating murine leukemia EARAD-^ has also 
been reported by Burchenal (19). In that study, 7 of 10 mice were 
cured with ara-c 10 mg/kg on days 3-7 followed by asparaginase 500 RJ/kg 
on day 7- In addition, a direct comparison between the studies of 
Berchenal and those reported here is complicated by different animal tumor 
model, dosage schedules for ara-c, and intervals betewen ara-c and 
asparaginase. However, analysis of these two studies raises the 
possibility that the 120 hours interval between ara-c and asparaginase 
used in this project may not be critical and that further studies 
are needed to define the precise schedule dependency of this combination. 
In view of the efficacy of the sequential administration of 
ara-c, then asparaginase in vivo as described above, experiments 
were conducted in cell culture to define the nature of the drug-drug 
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interaction devoid, of host-mediated effects. Prior to investigating 
the effects of the combination on cell viability, it was necessary, 
as before, to determine when the cells begin to recover from ara-c 
toxicity. Therefore, an in vitro growth curve as described under 
Methods was done. A typical growth curve is presented in Figure 3 and 
it shows that following a 2-hour lag, the ara-c pretreated cells begin 
to rapidly increase in number. In fact, the shorter doubling time 
for the midpoint of the ara-c curve (6.8 hours) as compared to the 
control (11.0), suggests that ara-c pretreatment may have partially 
synchronized the cells. The synchronization with ara-c will be dis¬ 
cussed in detail below. 
Data derived from the in vitro growth curve implied that cells 
resume active growth 2 hours after ara-c’s removal. Therefore, if 
asparaginase treatment was to precede the recovery of cells from ara-c, 
the addition of asparaginase would have to be within 2 hours of drug 
removal. Since 90 minutes is the minimum time for washing a large 
number of samples, this was selected as the time interval between 
treatments in the cell viability studies. The treatment schedule and 
results of these experiments are presented in Table 2. At a concen¬ 
tration of 10"6 M, ara-c was moderately toxic with a mean viability of 
52.8%. The dose of asparaginase chosen (0.5 IU/ml), however, was more 
lethal and the mean viability was only 23%. The evaluation of the com¬ 
bination requires an understanding of the anticipated response. For 
in vitro cell viability studies, an additive response is defined 


















HOURS AFTER DRUG REMOVAL 
Figure 3: Outgrowth of L5178Y cells in culture following 
8 hours of treatment with either normal saline( t ) or 
ara-c ( X ). 
':o 
a response with greater cell kill is considered synergistic (158). 
Using this definition, an additive response for ara-c plus aspara¬ 
ginase would be expected to result in a 13$ viability. The 7$ via¬ 
bility observed for the sequential treatment with ara-c and then 
asparaginase is at least additive if not synergistic. However, the 
simultaneous addition of both drugs (22.8$) was no more effective 
than asparaginase alone (23.0$). Furthermore, when asparaginase pre¬ 
ceded ara-c (50.3$) an antagonistic response occurred with the com¬ 
bination being significantly less effective than asparaginase alone 
(p >.005). These results support the schedule-dependent synergy and 
antagonism observed in vivo. 
To determine if the 90 minute interval between treatments was 
critical, two experiments were performed using the protocol outlined 
in Table III and the normalized results are also presented in Table IV. 
Figure 4 is a graphic representation of the means of both experiments 
expressed as a percentage of the anticipated additive response for both 
drugs versus the time post-wash. This graph shows that the synergis¬ 
tic response observed when ara-c precedes asparaginase is lost when the 
interval between treatments exceeds 90 minutes. In conjunction with 
the data from the growth curve, this result implies that for aspara¬ 
ginase to be effective, the cells must be treated prior to their re¬ 
sumption of active growth following ara-c. 
The curve for treatment group 5 (asparaginase preceding ara-c) 
in Figure 4 suggests that the longer the interval between the two 




Effect of different treatment schedules on cell viability in vitro 
Ara-c=10”°M. Asn'ase=asparaginase 0.5 IU/ml. Viability expressed 
as a percentage of control + one standard deviation. 
Protocol I Treatment 11 Wash I Treatment 21 Wash Viability No. Exp. 
'S hours '90 min. 8 hours 
I Saline Saline 100 
II Saline Ara-C 52.8 + 19.3 10 
III Saline Asn' ase 23.0 + 11.1 10 
IV Ara-C Asn' ase 7.0 + 4.0 4 
V Asn' ase Ara-c 50.3 + 17.4 4 
VI Saline Ara-c plus 
Asn' ase 
22.8 + 5.7 9 
Statistical Significance (Student's T test) 
II vs IV P .001 
II vs V NS 
II vs VI P .005 
III vs IV P .025 
III vs V P .005 
III vs VI NS 
V vs IV P .001 
NS=not significant 
. -X'f '• 
Table III 
The Effects of the Treatment Interval on Cell Viability in Vitro 
Group Treatment 1 Treatment 2 
I Saline Saline 
II Saline Ara-c 
III Saline Asparaginase 
IV Ara-c Asparaginase 
V Asparaginase Ara-c 
VI Saline Ara-c plus Asparaginase 
TREATMENT INTERVALS 
Begin Wash 
t TREATMENT 1 TREATMENT 2 
* n o Hours 













A - 1 hr. overlap 
B - 90 min. 
C - 4 hours 
Group Viability (%> of Control) 
EXP 1 EXP 2 
I 100 100 
II 72 87 
III 30 44 
IV 12 10 
V 71 68 
VI 28 24 
I 100 100 
II 54 64 
III 30 22 
IV 13 5 
V 53 72 
VI 30 14 
I 100 100 
II 56 46 
III 33 10 
IV 36 18 
V 50 42 
VI 24 15 
I 100 100 
II 24 58 
III 17 10 
IV 17 14 
V 38 57 
VI 23 28 










































Figure 4: Effect of the treatment interval on cell viability as a 
percentage of the expected response (as explained in text) following 
treatment with both ara-c and asparaginase. The line at 330% 
is equal to the effect of asparaginase alone as a percentage of the 
anticipated additive response. Data points=average of two experiments. 
4 teAJ'ase then as*,-p 
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appears that ara-c is actually rescuing cells Prom asparaginase toxicity. 
However, an alternate explanation can be derived from the pre- and 
post-wash cell counts. In contrast to ara-c, when cells are washed 
following this dose of asparaginase, there is a mean cell loss of 75% 
as compared with the pretreatment cell number. This implies that 
the cytotoxicity of asparaginase is underestimated by the cell viability 
since there is a large degree of lymphocytolysis. Cell lysis following 
asparaginase has been previously reported (136, 139)- The longer 
the interval post-asparaginase the greater the number of cells that can 
express the lytic affect of asparaginase toxicity. Therefore, since 
cloning only represents the viability of intact cells, the apparent 
antagonism of this combination at treatment intervals of 4 or 8 hours 
may be only artifactual because asparaginase's toxicity is under¬ 
estimated. 
The data presented above strongly supports the superiority of 
the sequential administration of ara-c and asparaginase. One possible 
explanation for the efficacy of this drug regimen is that ara-c pre¬ 
treatment potentiates the effect of asparaginase on macromolecular 
synthesis. To explore this hypothesis, the effect of asparaginase on 
the rate of DNA. synthesis as measured by TdR incorporation in cell cul¬ 
ture following ara-c treatment was determined as described above and 
the results are summarized in Table IV. Contrary to the above hypo¬ 
thesis, both the ara-c pretreated and the control group had approximately 





Effect of Asparaginase on H TdR incorporation 210 minutes after 
beginning washing following 8 hour pretreatment with either 
saline or ara-c 10“°M. Data represents the mean and standard 
deviation of 6 experiments. Rate=dpm/10b cells/minute incubation. 
Protocol Rate 
Control 15220 
Control + Asparaginase 5925 
Ara-c 21390 
Ara-c + Asparaginase 9075 
^Control % Inhibition 
+ 3618 
+ 893 61.1% 
+ 4685 V\l% 
+ 1153 57.8% 
Table V 
Effect of Asparaginase on H^TdR incorporation 210 minutes after 
beginning washing following 8 hour pretreatment with either saline, 
ara-c 5 X 10-6m or ara-c 5 X 10“7m. Data represents the mean of 
two experiments. Asparaginase=0.5 IU/ml as described in text. 
Rate=dpm/10b cells/minute of incubation. Control is the same as 
in Table IV. 
Protocol Rate % Control % Inhibition 
Control 
15220 
Control + Asparaginase 5925 61.U6 
Ara-C (5 X 10"6M) 8888 41.6/6 
Ara-c (5 XA10"6M + 
Asparaginase % 




Ar£HC (5 XAS’parSginase) 
8062 50.7% 
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asparaginase. Furthermore, In order to exclude the possibility 
that the degree of inhibition with asparaginase might be a function 
of the concentration of ara-c used, the results of three different 
dosages (5 X 10-^, 1 X 10-^ and 5 X 10“^) were determined and are 
summarized in Table V and the variation in inhibition ranging from 
50 to 58 percent is probably not significant. 
Finally, studies were undertaken to determine if the percentage 
inhibition of DNA synthesis induced by asparaginase was constant 
at different times post-wash. These results are presented in Table 
A/I and Figures 5} 6. As expected. Figure 5 demonstrates a constant 
rate of DNA synthesis for the control. However, following ara-c's 
removal DNA synthesis is initially inhibited but at 210 minutes, 
it reaches a peak of lHl% of control. This curve suggests S-phase 
synchronization and will be discussed in detail below. Figure 6 
shows that although both the rate of DNA synthesis and the percentage 
inhibition with asparaginase is constant for the control, following ara-c 
pretreatment, there is variation in both parameters. Even though 
this graph represents the average of only two experiments, the general 
configuration of the curve suggests that the higher the rate of DNA 
synthesis, the greater the inhibition induced by asparaginase. The 
significance of this finding is difficult to determine in light of two 
contradictory lines of evidence. First, although the rate of DNA 
synthesis 210 minutes post-wash in the ara-c pretreated group is lhl% 
of control (Figure 5), the percentage inhibition with asparaginase in 




Effect of the post wash interval on TdR incorporation with and 
without asparaginase following either saline or 10-oM ara-c for 
8 hours. Asn’ase=asparaginase 0.5 IU/ml. $ Control= rate of 
ara-c divided by the rate of control. Results are the average of 
two experiments. Rate=dpm/10b cells/minute incubation. 
Time Group Rate Rate with Asn’ase ^Inhibition $ Control 
90 min. Control 17128 6993 59.2% 
Ara-C 8820 4908 44.4% 51.5% 
210 min. Control 1806 7 6540 63. 8% 
Ara-C 26763 10086 62.3$ 148$ 
6 hours Control 18067 6110 66.2% 
Ara-C 14632 7752 47.0$ 80.1$ 
8 hours Control 17168 5905 66.6% 
Ara-C 20662 6445 70.1$ 120$ 
10 hours Control 19377 7645 60.5$ 
Ara-C 19955 8395 67.9% 103$ 
. sTjjori 8 
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Figure 5: Effect of the post wash interval following ara-c 
on the rate of TdR incorporation into DNA. Each point is the 
average of two experiments. (X)=normal saline (l)=ara-c 
0-o =0utgrowth curve for cell number following ara-c 
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HOURS... AFTER DRUG REMOVAL 
Figure 6: Exponetially growing L5178Y cells were treated with ara-c 
for 8 hours and then the rate of DNA synthesis and the inhibitory 
effect of 0.5 IU /ml of asparaginase on DNA synthesis was determined 
as a function of time after removal of ara-c. (0)=Rate of DNA synthesis 
(dpm/10° cells /minute incubation) . (¥)=% inhibition with asparaginase. 
Sir' 
asparaginase is greater at 210 minutes in the ara-c pretreated group 
than at 90 minutes, one would expect asparaginase to induce a greater 
cell kill at 210 minutes. In fact, the viability studies previously 
discussed showed equivalent cytotoxicity for both time intervals 
(Table III, Figure 4). In summary, these experiments do not support 
the hypothesis that ara-c potentiates the asparaginase-induced inhibi¬ 
tion of DNA synthesis. 
An alternate hypothesis for the synergy of this combination 
can be proposed based on the observation in Figure 5- The higher 
than control rate of DNA synthesis post ara-c (l4l$ of control at 
210 minutes) is consistent with partial S-phase cell synchronization 
and thus, a higher percentage of cells are susceptible to the effects 
of a DNA synthesis inhibitor. Therefore, since asparaginase has been 
shown to inhibit DNA synthesis (24, 47, 66, 96, 148), the consequences 
of an equivalent degree of inhibition on more cells should result 
in greater cytotoxicity. This argument is based, however, on the assurrp 
tion that asparaginase is an S-phase specific agent. In fact, the 
literature review above Implies that the non-S-phase specific inhibi¬ 
tion of membrane synthesis may be a more important component of 
asparaginase’s mechanism of action than is asparaginase-induced inhibi¬ 
tion of DNA synthesis (48, 117). In addition, an enhanced rate of DNA 
synthesis is not adequate evidence for the synchronization of tumor 
cells. 
In an attempt to prove that ara-c synchronizes tumor cells in 
this tumor model and at this dosage, the labeling index and mitotic 
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index were determined and the results presented in Table VIII. A 
labeling index of 96$ was observed for the first post-ara-c point 
which is consistent with virtually a pure S-phase population. Fur¬ 
thermore, the mitotic index for these cells 90 minutes post-wash 
was only 0.8% and after 6 hours, when the cells were able to traverse 
S-phase, the mitotic index reached a peak of 15.3$. However, this 
result is mitigated by a control labeling index of 75$ suggesting 
that under these culture conditions the control cells spend three- 
fourths of the cell cycle in S-phase. In addition, the mitotic index 
for the ara-c pretreated cells never exceeds that of the control. 
This may, however, only imply that the peak mitotic index following 
ara-c occurred at a time different from the data points chosen. Even 
though the data from the mitotic and labeling indexes suggest cell 
synchronization with ara-c, it also implies that the L5178Y tumor 
model used in these experiments is an inadequate system from which to 
draw definite conclusions on the S-phase specificity of asparaginase. 
Since numerous investigators have demonstrated cell synchronization 
with ara-c (1, 8, 42, 85, 127, 159, 164), the investigation of the 
interactions of ara-c and asparaginase in another tumor model with a 
slower rate of growth migjnt be of considerable value. 
In addition to demonstrating cell synchronization, the auto¬ 
radiographic data helps to clarify the mechanism by which ara-c causes 
cell death. Many studies as reviewed above have suggested that ara-c's 
cytotoxicity is the result of competitive DNA polymerase inhibition 




L5178Y cells in culture were treated with ara-c 10 for 8 
hours and following the removal of the drug, the labelling index 
'(autoradiograms) and mitotic index were determined as a function 
or time. Results represent the mean of 1000 cells counted. 
Time Post Wash Condition Labelling Index Mitotic Index 
90 minutes Control 80.8% 7.3% 
Ara-C 95.5% 0. 8% 
210 minutes Control 84.0% 8.3% 
Ara-C 94.0% 3.6% 
6 hours Control 82.2% 15.9% 
Ara-C 82.1% 10.5% 
8 hours Control 77.9% 10.95? 
Ara-C 68.3% 15.35S 
10 hours Control 78.8% 12.3% 
Ara-C 85.5% 8.3% 
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cell damage Induced by high doses of ara-c is either not reversed 
or only partially reversed by dCTP. This irreversible component of 
ara-c’s action could result from failure of the DNA polymerase to 
recover following removal of the drug. However, the 96% labeling 
index following ara-c’s removal shows that the DNA polymerases are 
functioning in virtually all cells and despite this, only 53% of the 
cells are viable by cloning (Table II). These results support the con¬ 
clusions of others (32, 84, 165) that ara-cTs cytotoxicity is not ade¬ 
quately explained by the observed competitive inhibition of DNA poly¬ 
merases . 
Since the data presented for the effect of asparaginase on DNA 
synthesis do not completely explain the observed synergistic response, 
the effect of ara-c on other macromolecules was investigated. Al¬ 
though it has been reported that ara-c does not inhibit protein syn¬ 
thesis directly (143), the effect of ara-c pretreatment on protein 
synthesis was investigated to rule out the possibility that ara-c 
potentiates the inhibition of protein synthesis by asparaginase. 
The effects of asparaginase on protein synthesis, 90 and 210 minutes 
after removal of ara-c, is presented in Table VIII. At 210 minutes, 
asparaginase caused 84.7% inhibition in both groups. Furthermore, 
the difference between 90% inhibition for the control and 77% follow¬ 
ing ara-c at 90 minutes is probably not significant, but it is difficult 
to draw conclusions based on a single experiment. However, considering 
both time points, it seems unlikely that ara-c profoundly effects 






Effect of post wash interval on H leucine incorporation with and 
without asparaginase follwoing either saline or 10-DM ara-c for 
8 hours. Data represents a single experiment. Asn'ase=asparaginase 
0.5 IU/ml. Rate=dpm/10Dcells / minute incubation. % Control= 
rate of ara-c divided by the rate of control. 
Time Group Rate Rate with Asn'ase % Inhibition % Control 
90 min. Control 1798 176 90.2% 
Ara-C 1868 433 76.8% 104% 
210 min. Control 1598 245 84.7% 
Ara-C 2752 422 84.7% 172% 
Table IX 
•3 
Effect of asparaginase on H ara-c incorporation into cold acid 
precipitalbe material. Data represents the mean of 4 experiments 
when either saline or asparaginase(0.5 IU/ml) was added at the 
beginning of a 4 hour incubation, 
mean rate + 1 standard deviation. 
Saline 158 + 11.7 
Asparaginase 60 ± 3.8 
Data is expressed as the 
Rate =dpm/10b cells/minute incubation. 
61.2$ inhibition with asparaginase 

impossible from this data to exclude an interaction on a specific 
protein. 
In summary, the data presented for the effect of the combina¬ 
tion of ara-c and asparaginase on DNA and protein synthesis does not 
substantiate the hypothesis that ara-c potentiates the biochemical 
effects of asparaginase. Therefore, an alternate theory must be pro¬ 
posed to explain why this combination is most effective in vitro 
when asparaginase is added to the cells within 90 minutes of ara-c’s 
removal (Table III). The schedule dependency of this combination 
suggests favorable cytokinetic timing so that asparaginase’s inhibi¬ 
tion of protein synthesis occurs at a critical time to the cell. 
Furthermore, since the initiation of DNA synthesis requires protein 
synthesis (63, 121, 140), the process of recovering from ara-c's 
toxicity might be associated with an increased demand for protein 
synthesis. In fact, the results in Table VIII show that following ara-c, 
the rate of protein synthesis is 172% of control at 210 minutes. 
Thus in terms of cytotoxicity, these cells may be more sensitive to 
an equivalent degree of inhibition with asparaginase. 
Further research could be directed at elucidating which specific 
proteins are required for cells to recover from ara-c and what are 
the effects of asparaginase on the synthesis of these proteins. Of 
particular interest would be the effect of this combination on the 
cellular levels of the « and/£ DNA polymerases. Since the oc poly¬ 
merase is required for DNA replication (11, 27, 28), inhibition of its 
synthesis by asparaginase would prevent the cells from reinitiating 
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cell growth following ara-c. Furthermore, if asparaginase inhibits 
the synthesis of the repair enzyme, polymerase (160), the cells 
would be unable to excise the ara-c incorporated into DMA, thus 
potentiating the toxicity of ara-c. Therefore, if asparaginase inhibited 
the synthesis of either oc or 0 DNA polymerase, it could explain the 
schedule-dependent synergy of this combination. 
Another biochemical locus that might be affected by the com¬ 
bination of ara-c and asparaginase is histone synthesis. Histone 
synthesis is an S-phase event that is necessary for the assembly 
of newly-formed DNA complexes (131). Boren et al. have demonstrated 
a specific Inhibition of histone messenger RNA and histone synthesis 
by ara-c (12, 135). Furthermore, since asparaginase inhibits protein 
synthesis (24, 47, 95, 96, 138, 147, 148, 163) probably including 
inhibition of histone synthesis, the combination might produce an 
additive or synergistic inhibition of histone synthesis. Confirmation of 
this hypothesis would require direct measurement of histone synthesis 
following this combination. 
It is also possible that the synergistic cell kill produced by 
the sequential administration of ara-c and asparaginase results from 
an enhanced rate of RNA catabolism. Asparaginase might increase 
the destruction of RNA as a result of higher levels of ribonuclease, 
an enzyme that hydrolyses RNA. In fact, asparaginase has been reported to 
increase ribonuclease in murine lymphosarcoma P1798 (2). Furthermore, 
Boren et al. (12, 135) demonstrated that ara-c decreased the transla¬ 
tion of 7-9 S mRNA. Therefore, the combination of enhanced destruction 
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and decreased translation of RNA would indeed be a serious cellular 
lesion. However, this mechanism for drug synergy is only hypothetical 
and further research is necessary to demonstrate that an enhanced turn¬ 
over of RNA indeed occurs. 
The biochemical studies presented above were undertaken to explain 
the observed additive or synergistic response of the sequential ad¬ 
ministration of ara-c followed by asparaginase, but they provide 
no explanation of the antagonism of the reverse combination. There¬ 
fore, a small group of experiments was done to try to understand 
the observed antagonism. Based on the hypothesis that ara-c Ts cyto¬ 
toxicity was associated with the incorporation of ara-c into RNA and 
DNA, the effect of asparaginase treatment on ara-c's incorporation 
into TCA precipitable macromolecules was investigated. The method 
used gives only the sum of the incorporation of ara-c into RNA and 
DNA and does not differentiate between them. The results presented 
in Table IX confirm the findings of other investigators that ara-c 
is incorporated into macromolecules (29, 32, 38, 56, 143, 166), and 
that the incorporation is linear over 4 hours (Figure 7)• Table IX 
also shows that asparaginase caused a 6l% inhibition of ara-c's 
incorporation into macromolecules suggesting that this may be a mech¬ 
anism of antagonism. This antagonism could result from asparaginase 
inhibiting the transport of ara-c into the cells as has been pre¬ 
viously demonstrated in the L5178Y leukemia cells by Nahas and Ca- 
pizzi (107). Following asparaginase treatment, they observed decreased 
intracellular concentrations of ara-c, methotrexate, 6-mercaptopurine 
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and 5-fluorouracil. They concluded that this effect is a nonspecific 
membrane defect that might result from asparaginase’s inhibition of 
membrane glycoprotein synthesis. An alternate explanation for as¬ 
paraginase’s antagonism of ara-c’s incorporation is that asparaginase’s 
inhibition of cellular DM synthesis prevents incorporation of this 
cytidine analog. 
In order to differentiate between these two possible mechanisms 
of antagonism, asparaginase was added to the cells after two hours 
of incubation with H ara-c, which is a tune when the intracellular 
steady state concentration of ara-c should have already been reached. 
Therefore, if inhibition with asparaginase occurred after this addition, 
it could be assumed not to be associated with a transport defect. The 
observed change of slope of curve C in Figure 6 suggests that aspara¬ 
ginase directly inhibits ara-c incorporation into macromolecules 
independent of a membrane effect. However, this does not exclude 
the possibility that a membrane effect might coexist. This experi¬ 
ment represents only a preliminary study. Final proof that asparaginase 
antagonizes ara-c by preventing its incorporation into DM would 
require the separation of the effects of asparaginase on the incor¬ 
poration of ara-c into DM and RM and demonstrating that the intra¬ 
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Figure 7:Effect of asparaginase on H^ara-c incorporation into cold 
acid precipitable material. Data points represent the average of two 
experiments. (0)=control. (0) =asparaginase at time 0. 
(X) =asparaginase at 120 minutes as indicated by arrow. 
' 
Summary 
Ihe aim of this thesis project was to determine if the combina¬ 
tion of ara-c and asparaginase shows schedule-dependent synergy and/or 
antagonism in the treatment of murine leukemia L5178Y. Prior to 
investigating this possibility, in vivo tumor growth curves were 
determined as a basis for selecting treatment schedules. These studies 
showed that following either ara-c or asparaginase, the tumor burden 
rapidly falls and does not begin to recover until 120 hours post¬ 
treatment. Consequently, a 120 hour interval was chosen between 
drugs for the sequential treatment schedules in the animal survival 
studies. The mouse studies demonstrated that the sequential use of 
ara-c and then asparaginase resulted in synergistic animal survival. 
However, when asparaginase preceded ara-c or when both drugs were 
administered simultaneously, a subadditive or antagonistic response 
was observed. 
The schedule-dependent synergy and antagonism observed in vivo 
for the combination of ara-c and asparaginase was investigated further 
in vitro by cell viability studies. As before, an antagonistic response 
was observed for the sequential use of asparaginase and then ara-c 
and for the simultaneous treatment with both drugs. Furthermore, 
an additive, if not synergistic, response occurred following the 
sequential treatment with ara-c and then asparaginase, but this favorable 
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response was lost when the interval between drugs exceeded 90 minutes. 
The observation confirms the in vivo data and supports the importance 
of understanding drug-drug interactions. 
In an attempt to explain the observed synergy, the effect of 
the sequential administration of ara-c and then asparaginase on 
macromolecular synthesis in vitro was explored. Ara-c pretreatment 
did not potentiate the asparaginase-induced inhibition of DM syn¬ 
thesis. Furthermore, this lack of potentiation was not influenced 
by different doses of ara-c or by the time interval betewen ara-c 
and asparaginase. In addition, ara-c did not potentiate the effect 
of asparaginase on protein synthesis. 
A 
An enhanced rat ft of DM and protein synthesis, as compared to 
A 
control,was observed 210 minutes after ara-c*s removal. This observa¬ 
tion is consistent with ara-c induced partial cell synchronization and 
is supported in part by the results of the labeling and mitotic in¬ 
dices. However, in this tumor model the increase in S-phase cells fol¬ 
lowing ara-c is too small to account for the synergistic effect of the 
combination. Although no definitive mechanism can be proposed to ex¬ 
plain the observed synergistic response, it seems most likely that 
asparaginase is preventing the tumor cells from recovering from ara-c*s 
toxicity. Further implications of this and other mechanisms are 
discussed. 
Finally, data is presented that shows that asparaginase prevents 
ara-c*s incorporation into macromolecules. Since ara-c*s incorpora¬ 
tion into macromolecules is associated with its cytotoxicity. 
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inhibition of its incorporation could explain the antagonism of the se¬ 
quential use of asparaginase and then ara-c. 
It is hoped that the use of this data to devise a new treatment 
protocol for acute leukemia will result in an enhanced therapeutic 
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